Cybin Inc. (CYBN)
USD 6.5
(-1.81%)
USD 6.5
(-1.81%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 78.83 Million CAD | 53.03% |
| 2022 | 51.51 Million CAD | -19.3% |
| 2021 | 63.83 Million CAD | 107.78% |
| 2020 | 30.72 Million CAD | 1480.45% |
| 2019 | 1.94 Million CAD | 2314.19% |
| 2018 | 80.52 Thousand CAD | 0.0% |
| 2016 | 127.21 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 20.17 Million CAD | -19.36% |
| 2023 Q3 | 26.88 Million CAD | 93.26% |
| 2023 FY | 78.41 Million CAD | 52.2% |
| 2023 Q4 | 25.19 Million CAD | -6.28% |
| 2023 Q2 | 13.91 Million CAD | 3.84% |
| 2023 Q1 | 13.39 Million CAD | -2.25% |
| 2022 Q4 | 13.7 Million CAD | 13.31% |
| 2022 Q3 | 12.09 Million CAD | -1.9% |
| 2022 Q1 | 13.39 Million CAD | -18.01% |
| 2022 Q2 | 12.32 Million CAD | -7.97% |
| 2022 FY | 51.51 Million CAD | -19.3% |
| 2021 Q2 | 17.06 Million CAD | 22.42% |
| 2021 Q3 | 16.45 Million CAD | -3.57% |
| 2021 Q1 | 13.93 Million CAD | 12.74% |
| 2021 FY | 63.83 Million CAD | 107.78% |
| 2021 Q4 | 16.33 Million CAD | -0.71% |
| 2020 FY | 30.72 Million CAD | 1480.45% |
| 2020 Q3 | 11.37 Million CAD | 23171.13% |
| 2020 Q4 | 12.36 Million CAD | 8.66% |
| 2020 Q2 | 48.89 Thousand CAD | -98.89% |
| 2020 Q1 | 4.42 Million CAD | 0.0% |
| 2019 Q3 | 236.55 Thousand CAD | 0.0% |
| 2019 FY | 1.94 Million CAD | 2314.19% |
| 2018 FY | 80.52 Thousand CAD | 0.0% |
| 2016 FY | 127.21 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | -145.779% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -576.762% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | -51.605% |
| Azitra, Inc. | 8.3 Million USD | -849.557% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -782.032% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -1048.83% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | -171.923% |
| CEL-SCI Corporation | 31.47 Million USD | -150.463% |
| iBio, Inc. | 16.85 Million USD | -367.62% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | -138.846% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | -290.618% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | -217.094% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | -511.227% |
| NanoViricides, Inc. | 8.51 Million USD | -825.728% |
| Oragenics, Inc. | 5.45 Million USD | -1346.014% |
| BiomX Inc. | 26.81 Million USD | -194.011% |
| BiomX Inc. | 26.81 Million USD | -194.011% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | -145.963% |
| Palatin Technologies, Inc. | 34.67 Million USD | -127.387% |
| Scorpius Holdings, Inc. | 39.81 Million USD | -98.002% |
| Theriva Biologics, Inc. | 21.43 Million USD | -267.86% |